HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Other

BioCentury

1
Articles
Mentioned
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
0.95
Relevance Score

Coverage Timeline

April 2026
Apr 11, 2026
The numbers support the pivot: a 2026 BioCentury survey found over half of preclinical CFOs shifting at least 20% of their planned R&D outlays from open-ended platform work to focused product development and biosafety validation.
Related Companies